Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Telaprevir

FDA-approved product (tablet, oral), marketed as Incivek.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Telaprevir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Antivirals for treatment of hcv infections
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP02

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Telaprevir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Telaprevir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)

    NCT02006745 · start 2014-01

    Registered record
    Registry ID
    NCT02006745
    Conditions
    HIV
    Interventions
    Ribavirin; Telaprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-01
    Completion
    2016-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionRibavirin; Telaprevir
    PhasePhase 3
    Registry statusCompleted

  • Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1

    NCT01994486 · start 2013-12

    Registered record
    Registry ID
    NCT01994486
    Conditions
    Hepatitis C, Chronic
    Interventions
    Telaprevir and Sofosbuvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-12
    Completion
    2014-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionTelaprevir and Sofosbuvir
    PhasePhase 2
    Registry statusCompleted

  • Register of Telaprevir and Boceprevir in Routine Clinical Practice

    NCT02004379 · start 2013-11

    Registered record
    Registry ID
    NCT02004379
    Conditions
    Hepatitis C
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-11
    Completion
    2015-06
    Enrolment
    1,553

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection

    NCT01872936 · start 2013-06

    Registered record
    Registry ID
    NCT01872936
    Conditions
    Hepatitis C, Chronic
    Interventions
    Miravirsen; Telaprevir; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2013-06
    Completion
    2015-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionMiravirsen; Telaprevir; Ribavirin
    PhasePhase 2
    Registry statusUnknown

  • Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

    NCT01858961 · start 2013-05

    Registered record
    Registry ID
    NCT01858961
    Conditions
    Hepatitis C, Chronic
    Interventions
    BI 201335; ribavirin; BI 207127; Telaprevir; ribavirin; Pegylated Interferon
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2013-05
    Completion
    2016-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionBI 201335; ribavirin; BI 207127; Telaprevir +2 more
    PhasePhase 3
    Registry statusWithdrawn

  • An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

    NCT01701063 · start 2013-01

    Registered record
    Registry ID
    NCT01701063
    Conditions
    Hepatitis C
    Interventions
    Telaprevir; Peginterferon alfa-2b; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2013-01
    Completion
    2015-04
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTelaprevir; Peginterferon alfa-2b; Ribavirin
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

    NCT01718158 · start 2013-01

    Registered record
    Registry ID
    NCT01718158
    Conditions
    Hepatitis C
    Interventions
    Peginterferon Lambda-1a; Peginterferon Alfa-2a; Ribavirin; Daclatasvir; Telaprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-01
    Completion
    2014-10
    Enrolment
    444

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionPeginterferon Lambda-1a; Peginterferon Alfa-2a; Ribavirin; Daclatasvir +1 more
    PhasePhase 3
    Registry statusCompleted

  • A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects

    NCT01718145 · start 2012-11

    Registered record
    Registry ID
    NCT01718145
    Conditions
    Hepatitis C Virus Infection
    Interventions
    Daclatasvir; Asunaprevir; Ribavirin; pegIFNα-2b; Telaprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-12
    Enrolment
    258

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Virus Infection
    InterventionDaclatasvir; Asunaprevir; Ribavirin; pegIFNα-2b +1 more
    PhasePhase 3
    Registry statusCompleted

  • Dose Ranging of GSK2336805 in Combination Therapy

    NCT01648140 · start 2012-08-01

    Registered record
    Registry ID
    NCT01648140
    Conditions
    Hepatitis C, Chronic
    Interventions
    GSK2336805 40 mg; GSK2336805 60 mg; Pegylated interferon alpha-2a; Ribavirin; Telaprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-08-01
    Completion
    2014-07-16
    Enrolment
    286

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionGSK2336805 40 mg; GSK2336805 60 mg; Pegylated interferon alpha-2a; Ribavirin +1 more
    PhasePhase 2
    Registry statusCompleted

  • VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

    NCT01581138 · start 2012-07

    Registered record
    Registry ID
    NCT01581138
    Conditions
    Chronic Hepatitis C Virus
    Interventions
    VX-222; telaprevir; ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-07
    Completion
    2013-12
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C Virus
    InterventionVX-222; telaprevir; ribavirin
    PhasePhase 2
    Registry statusCompleted

  • Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

    NCT01597895 · start 2012-07

    Registered record
    Registry ID
    NCT01597895
    Conditions
    Healthy
    Interventions
    Maraviroc; Maraviroc + Boceprevir; Maraviroc + Telaprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-07
    Completion
    2012-08
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMaraviroc; Maraviroc + Boceprevir; Maraviroc + Telaprevir
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment

    NCT01600976 · start 2012-06

    Registered record
    Registry ID
    NCT01600976
    Conditions
    Hepatic Impairment
    Interventions
    telaprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-06
    Completion
    2012-11
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment
    Interventiontelaprevir
    PhasePhase 1
    Registry statusCompleted

  • Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518)

    NCT01544582 · start 2012-05

    Registered record
    Registry ID
    NCT01544582
    Conditions
    Hepatitis C Chronic
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-05
    Completion
    2015-07
    Enrolment
    713

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Chronic
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir

    NCT01635829 · start 2012-05

    Registered record
    Registry ID
    NCT01635829
    Conditions
    Healthy Participants
    Interventions
    Telaprevir; Phenytoin; Carbamazepine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-05
    Completion
    2012-09
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionTelaprevir; Phenytoin; Carbamazepine
    PhasePhase 1
    Registry statusCompleted

  • Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms

    NCT01641094 · start 2012-05

    Registered record
    Registry ID
    NCT01641094
    Conditions
    Chronic Hepatitis C
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-05
    Completion
    2014-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted